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Abstract 
Fluorine-containing nucleoside analogues represent a significant class of FDA approved 
chemotherapeutics widely used in the clinic. The incorporation of fluorine into drug-like agents 
modulates lipophilic, electronic and steric parameters thus influencing pharmacodynamic and 
pharmacokinetic properties of drugs. Fluorine can block oxidative metabolism of drugs and the 
formation of undesired metabolites by changing H-bonding interactions. In this review, we focus 
our attention on chemical fluorination reagents and methods used in the nucleoside analogues field, 
including PET radiochemistry. We briefly discuss both the cellular biology and clinical properties 
of FDA-approved and fluorine-containing nucleoside/nucleotide analogues in development as well 
as common resistance mechanisms associated with their use. Finally, we emphasize pro-nucleotide 
strategies used to improve therapeutic outcome of nucleoside analogues in the clinic.  
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Introduction 
Over the last three decades medicinal fluorine chemistry has significantly evolved into an area of 
interest for many scientists. Incorporation of fluorine atoms(s) into a drug-like molecule can impart 
a range of chemical, physical and biological properties. Combining the benefits of fluorine 
substitution with the established nucleoside class therapeutics has led to a number of clinically 
proven drug molecules used in both antiviral and anticancer therapy. Indeed, among fifteen FDA-
approved pyrimidine and purine-based cytotoxic antimetabolites, the fluorine-containing nucleoside 
analogues make up a significant class of chemotherapeutics widely used in the clinic (Figure 1). In 
this review we focus on nucleophilic and electrophilic methods of fluorination and highlight novel 
and interesting synthetic strategies towards fluorinated nucleoside analogues (NAs). In addition, we 
outline the role 18F plays as a radioisotope in PET imaging. We discuss the cellular biology and 
clinical properties of FDA approved fluorine-containing nucleoside/nucleotide analogues as well as 
those in clinical development. Furthermore, we emphasize strategies designed to circumvent the key 
resistance mechanisms associated with NAs thus improving their therapeutic efficiency in the 
clinic.  
 
 
 
Figure 1. FDA-approved fluorinated anticancer and antiviral nucleoside analogues. 
 1. Overview of fluorine chemistry applied to nucleosides 
More than 20% of medicines and novel drug candidates are estimated to contain fluorine within 
their chemical structure [1][2], and the special properties of fluorine within the context of drug 
discovery are summarised in Figure 2 and detailed below. Fluorine has been extensively exploited 
in the drug discovery and development process, but its incorporation has historically been limited 
by synthetic chemistry challenges. 
  
 
Figure 2. Structure and properties of the fluorine atom 
 
Fluorine has the capability to increase the lipophilicity (logP), which together with the molecular 
size influences the membrane permeability of a molecule, playing a critical rule in the optimization 
of drug candidates’ oral bioavailability. The status of fluorine as the most electronegative atom in 
the periodic table (3.98 on the Pauling scale) also affects the acidic and basic properties of nearby 
functional groups by modifying the pKa of the molecule. This will influence its toxicity, selectivity, 
potency, and both pharmacodynamic and pharmacokinetic properties. Furthermore, the highly 
polarized C-F bond will often provide better stability to the molecule itself. As fluorine is a very 
small atom similar in size to H (van der Waals radius of 1.47 Å compared to 1.20 Å for H), fluorine 
is commonly used to substitute the H or the OH group in bioactive molecules causing minimal 
steric perturbation. However, by changing H-binding interactions, it can block oxidative 
metabolism and the formation of undesired metabolites [3][4].  
The presence of a fluorine atom in the ribose ring of nucleoside analogues may have a 
significant impact on the conformation of nucleosides. It affects the dipole-dipole and gauche 
interactions, the anomeric effect, and the F-base interactions. Predictions on the activity of each 
single nucleoside are difficult to make, as the outcome of its conformation is dependent on each 
substitution. Generally, fluorine in the 2’--position of the ribose favours a south conformation of a 
molecule, which is often linked to enhanced anti-HIV activity for example, whereas the fluorine in 
the 2’--position favours a north conformation (Figure 3). Nevertheless this rule doesn’t apply to all 
fluorinated nucleosides. The pro-nucleotide CycloSal triesters of ara- and ribo-configurated 2′-
fluorinated-2′,3′-dideoxyadenosines (F-ddA) were used to study the effects of the two different 
sugar pucker conformations induced by two opposite  and  configurations of the fluorine at C2′ 
of the dideoxyribose moiety. F-ara-ddA is an active anti-HIV agent, whereas the ribo-analogue is 
inactive. Interestingly, the ribo-configured phosphotriesters prepared from the inactive F-ribo-ddA 
showed a level of anti-HIV activity that was even higher than that of F-ara-ddA [5]. Therefore 
stability and potential therapeutic activity of both conformations vary according to different 
substitutions on the nucleosides [6]. 
 
Figure 3. North and south conformation of two anomers of F-ddA 
 
Moreover, fluorine also has a remarkable role in Positron Emission Tomography (PET) due to the 
convenient half-life of its radioisotope 18F (109.8 min). A relatively short half-life allows synthesis 
of the tracer and the imaging process on the same day. In addition, 18F is also a low positron 
emission energy emitter giving a good spatial resolution for imaging. All these factors make it the 
optimal radioisotope for PET imaging and much effort has been put into the discovery of novel and 
efficient routes towards synthesis of novel 18F-PET tracers [7][8][9]. The glucose analogue 2-
[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) is the most ubiquitous PET tracer  with multiple 
applications in oncology, cardiology and neurology [9][10]. However, also many 18F-
nucleoside analogues are currently under clinical investigation as proliferation biomarkers, reporter 
imaging probes for personalised medicine and prediction tools of the response to nucleoside 
analogue chemotherapy [11]. The challenge of their synthesis is to incorporate the 18F-fluorine into 
the nucleoside analogues at a late stage in the synthesis so that the synthetic procedure and the 
imaging can occur within several half-lives to provide good quality scanning data. 
 
1.1 Fluorination chemistry: nucleophilic and electrophilic methods 
Numerous treatments against viral infections and cancer involve the use of nucleosides, nucleotides 
or their prodrugs, with many of them bearing a fluorine atom on the sugar or on the nucleobase 
moiety. Different synthetic strategies towards nucleosides have been extensively reviewed in recent 
years [12][13][14].  Herein we will describe some standard and novel interesting synthetic pathways 
towards fluorinated nucleoside analogues. 
The main approaches used for the synthesis of fluorinated nucleosides consist either in the 
fluorination of preformed nucleosides (divergent approach), which is particularly used in 18F-PET 
chemistry, or in the N-glycosylation of the nucleobase with a fluorinated substrate (convergent 
approach). 
 
1.1.1 Nucleophilic methods 
In terms of ease of synthesis, aliphatic fluorinations are the most straightforward, with several 
fluoride salts being used to perform nucleophilic reactions. Olah’s reagents (9 and 10, Figure 4) are 
useful when the conversion of secondary and tertiary alcohols is required, being selective for 
tertiary over the secondary alcohol. 
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Figure 4. Nucleophilic and electrophilic fluorinating agents 
 
Aliphatic nucleophilic fluorinations such as the one outlined in Figure 5 occur with SN2 
stereochemistry; good leaving groups and aprotic solvents are preferably required due to the low 
reactivity of fluoride. In PET chemistry crown ethers (such as Kryptofix 222TM) are used to enhance 
the weak nucleophilicity of 18F-fluoride so that the incorporation can happen in a fast and efficient 
way. 18FLT, the first human approved 18F-nucleoside as a tumour proliferation biomarker is 
synthesised through this approach. A rapid and facile synthesis of 18F-FLT consists in the use of 
two different precursor molecules (15 and 16), which need to be deprotected to give [18F]-FLT (18) 
after the fluorination step [15]. 
 
Figure 5. Synthesis of 18FLT via two approaches 
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Reagents and conditions: (a) K/(K222)18F, anhydr. DMSO, 160°C, 10min; (b) K/(K222)18F, anhydr. CH3CN, 135°C, 
5min; (c) 1N NaOH, 55°C, 10 min or 1N HCl, 105°C, 5 min. 
 
(Diethylamino)sulphur trifluoride (DAST) (11, Figure 4) is another versatile reagent for fluorination 
particularly useful in nucleoside chemistry. A fluorination reaction with DAST proceeds via an SN2 
mechanism consisting of displacement of the OH group with inversion of stereochemistry (Figure 
6) [16]. 
 
Figure 6. Synthesis of 2’-F-nucleoside (20) using DAST as fluorinating agent 
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Reagents and conditions: (a) DAST, pyridine, DCM, 40C 
 
This agent is used to convert primary, secondary, tertiary and allylic alcohols to fluorides, but also 
for the conversion of aldehydes and ketones to difluorides. Diethylaminodifluorosulfinium 
tetrafluoroborate (XtalFluor-E, 12) and morpholinodifluorosulfinium tetrafluoroborate (XtalFluor-
M, 13) shown in Figure 4 are newer fluorinating agents that are more thermally stable than DAST. 
They are used to convert alcohols to alkyl fluorides and carbonyl groups into gem-difluorides, being 
more selective than DAST and leading to fewer elimination side products [16]. Recently, several 
studies have been carried out to look for improved methods and substrates for nucleophilic 
fluorination reactions. Further developments have been applied also to radiochemistry, for example 
in the use of metal-catalysts for allylic fluorination reactions [17]. 
Nucleophilic aromatic fluorination is operationally more challenging than aliphatic 
fluorination, and in PET radiochemistry is often used to make radiolabelled arenes. High 
temperature and activated substrates with electron withdrawing groups on the aromatic rings in the 
ortho or para positions are commonly required to counter the normally disfavoured SNAr 
mechanism. When the aromatic group contains electron rich groups, a strategy has been developed 
to circumvent this issue, whereby an electron-donating group is masked with an electron 
withdrawing group using appropriate protecting group chemistry.  
In PET radiochemistry 18F- fluoride is commonly introduced into the aromatic moiety by the 
use of aryliodonium salts [8]. New studies focus in finding methods to improve reaction yields and 
new synthetic strategies to access the aryl fluoride. A number of transition metal catalysed 
nucleophilic fluorinations have been studied. For example, a novel approach uses nickel σ-aryl 
complexes as pre-catalysts to access 18F-fluorouracil (23), a PET tracer for cancer imaging (Figure 
7). This is the first application of a transition-metal-mediated fluorination for clinical application 
[18]. 
 
Figure 7. Synthesis of 18F-Fluorouracil (23) via transition-metal-mediated fluorination 
 
Reagents and conditions: (a) LnNiIIX2, pyridine, 70°C, 1h; (b) PhI(4-OMe-pyridine)2(OTf)2, (18-c-6)K18F, 
MeCN (0.5% H2O), 23°C, 1 min; (c) HCl, EtOH, 23°C, 2 min. 
 
1.1.2 Electrophilic fluorination 
Fluorination of aromatic rings and/or electron rich-double bonds can be achieved with the use of an 
electrophilic-fluorinating agent. Since most applications preclude the highly toxic and non-selective 
fluorine gas, fluorine must bind an electronegative atom such as nitrogen, activated by a strongly 
withdrawing group such as the sulfonyl group. This synthetic strategy is quite common in 
nucleoside chemistry when fluorination of a heterocyclic ring is required as depicted in Figure 8. A 
convenient electrophilic fluorinated agent is Selectfluor (14, Figure 4) which, compared to F2, is 
safer, solid and soluble in polar solvents. It can also be used in particular cases for fluorination of 
sugar moieties bearing an electron-rich double bond. 
 
Figure 8. Electrophilic fluorination with Selectfluor (14) 
 
 
Reagents and conditions: (a) Selectfluor, HOAc-H2O. 
 
1.2 N-glycosylation of fluorine-containing starting material 
The N-glycosylation reaction between (fluorinated) nucleobase and sugar moieties can be 
performed when later-stage fluorination is either not possible or convenient. This convergent 
approach is used particularly in the synthesis of 2’-β-fluoro nucleosides. First the fully-protected 
sugar (26) is brominated to form the 1-α-glycosyl bromide (27), formation of which leads 
preferentially to the formation of β-nucleoside (28) as reported in the synthesis of the antineoplastic 
agent clofarabine (6) (Figure 9) [19]. 
 
Figure 9. Synthesis of clofarabine (6) 
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Reagents and conditions: (a) HBr, AcOH, rt; (b) 2-chloroadenine, KOt-Bu, MeCN, t-AmOH, DCE, 55C; (c) cat. 
NaOMe, MeOH, rt. 
 This synthetic approach is commonly used also in PET chemistry for the synthesis of several 18F-β 
nucleosides as reported in the novel synthesis of 18FIAU, a reporter gene for the expression of the 
herpes simplex virus type-1 thymidine kinase (HSV1-tk) [20][21]. General synthetic approaches for 
the convergent synthesis of fluorinated nucleosides have recently been extensively reviewed by 
Schinazi et al [22].  
Several synthetic approaches have been investigated for the synthesis of gemcitabine (4), an 
established anticancer drug against pancreatic, breast and ovarian cancer.  The conventional scheme 
consists of a convergent synthesis where the 2-deoxy-2,2-difluororibofuranose derivative (29) is 
protected and activated, to further react with an activated cytosine. New linear synthetic approaches 
towards gemcitabine (4) have also been developed achieving moderate anomeric selectivity (Figure 
10) [23]. 
 
Figure 10. Linear synthesis of gemcitabine (4) 
O
FOBz
BzO
F OH
O
FOBz
BzO
F NH
O
NH2
O
FOBz
BzO
F
H
N NH
O
OEtO
NH
O
O
NO
FOBz
F
BzO
NH
N
O
NO
FOBz
F
BzO
N
N
N
NH2
ON
O
FOH
F
HO
29 30 31
32 33 4
a b c
d e
 
Reagents and conditions: (a) urea, dioxane, rt, 66 h; (b) (E)-3-ethoxyacryloyl chloride, MeCN, reflux, 18 h; (c) HCl, 
AcOH, rt, 24 h; (d) 1,2,4-triazole, 2-chlorophenyl phosphorodichloridate, pyridine, rt, 5 d; (e) 7N NH3, MeOH, rt, 36 h. 
 
Another recent study also shows advances in diastereoselective synthesis of 2’-fluoro-nucleoside 
analogues using an acyclic approach. Two nucleoside scaffolds, the 1′,2′-trans-furanosides (36) and 
1′,2′-cis-thiofuranosides (37) with a fluorine in the C2′-position have been synthesised using the 
following strategy with the potential to be applied to many other nucleosides (Figure 11) [24]. 
 
Figure 11. Diastereoselective synthesis of 2’-F- nucleoside analogues 
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Reagents and conditions: (a) I2, Silylated thymidine, THF, 25°C, 48 h; (b) HF-pyridine, THF, 25°C, 16 h (c) 
Me2S(SMe)BF4, THF, 25°C, 5 h; (d) MsCl, Et3N, anhydr. DCM, 25°C, 5 h; (e) 2,6-lutidine, 160°C, 48 h. 
 
1.3 Trifluoromethylation 
Direct trifluoromethylation of nucleoside analogues can be used as a synthetic approach towards 
trifluoromethylated nucleosides such as trifluorothymidine (TFT, 7) an agent with both anticancer 
and antiviral properties (Figure 12) [25].  
 
Figure 12. Synthesis of the anticancer and antiviral agent TFT (7) 
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Reagents and conditions: (a) Trifluoroiodomethane, DMSO, H2SO4, H2O, FeSO4, 40C. 
 
Recent studies concerning trifluoromethylation led to the development of a new synthetic pathway 
based on N-glycosylation of a trifluoromethylated-substrate obtained from an easily accessible 
building block as shown in Figure 13. Interestingly, the nucleosides were obtained with good β-
selectivities [26]. 
 
Figure 13. Synthesis of trifluoromethylated nucleoside analogue (46) 
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Reagents and conditions: (a) Sodium ethoxide, formamidine hydrochloride, EtOH, reflux, 16 h; (b) POCl3, reflux, 17 
h; (c) O3, DCM, MeOH, -78C, 15 min. then DMS, rt, 18 h; (d) NH3, EtOH, rt, 24 h, then p-TsOH, MeOH, rt, 19 h; (e) 
NaH, MeCN, 0C, 5 min., rt, 30 min. then 44, THF, rt, 16 h; (f) CF3COOH (90% in H2O, v/v), rt, 5 min. 
 
2. Synthesis of fluorinated nucleotide analogues - the phosphoramidate (ProTide) 
approach 
Despite the widespread utility of nucleoside analogues as both antiviral and anticancer agents, drug 
resistance represents a major problem for their clinical application. In order to express therapeutic 
activity, nucleoside analogues need to be phosphorylated by cellular kinases to the corresponding 
5’-mono-, di- and triphosphate forms. Although several synthetic strategies have been developed to 
access the active 5’-triphosphate form [27], they are not viable drug candidates due to their 
chemical instability and high polarity which disallow effective crossing of these species through 
cell membranes. In the activation pathway of nucleoside analogues the first phosphorylation is 
considered to be rate-limiting step therefore many approaches to develop prodrugs of nucleoside 
monophosphate forms have been developed [28]. 
The phosphoramidate technology also known as ProTide approach, developed by McGuigan 
and co-workers in 1995 is the most successful of the pro-nucleotide strategies. Phosphoramidates 
consist of a 5’-masked monophosphate moiety (built using: an amino acid ester and aryloxy group) 
introduced into the nucleoside template at the 5’-position, which, after cellular nucleoside-
transporter-independent uptake and subsequent intracellular metabolism, deliver the 5’-
monophosphate form [29]. Some anticancer and antiviral ProTides are characterized by the 
presence of fluorine in their chemical structure. The fluorinated nucleoside is used as substrate for 
their chemical synthesis as exemplified in Figure 14 for gemcitabine phosphoramidate NUC-1031 
(51) [30]. 
 
Figure 14. Synthesis of ProTide NUC-1031 (51) 
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Reagents and conditions: (a) DBOC, Na2CO3, 1,4-dioxane/H2O (4:1 v/v), rt, 48 h; (b) L-Ala benzyl ester tosylate salt, 
Et3N, dry DCM, -78C, 3 h; (c) tert-BuMgCl, THF, rt, 16 h; (d) TFA/DCM (1:1 v/v), 0C, 4 h. 
 
3. Fluorinated anticancer nucleosides  
Nucleoside analogues (NAs) are considered as cornerstones in the treatment of patients with cancer 
and viral infections since they were first introduced into clinical use over five decades ago. 
Nucleoside analogues are antimetabolites that mimic natural nucleosides in the way they are 
metabolised and exert biological activity. After cellular uptake using nucleoside-transporter systems 
NAs become substrates for specific nucleo(s)(t)ide kinases which convert them to the 5’-mono, -di 
and triphosphate forms. Such active molecules can interfere with the de novo synthesis of 
DNA/RNA precursors, which leads to the inhibition of DNA and RNA synthesis and eventually to 
suppression of cell growth and division. 
3.1 Pyrimidine-based anticancer fluorinated nucleoside analogues 
3.1.1 5-Fluorouracil and prodrugs 
One of the first FDA approved anticancer agents was 5-fluorouracil (1) (included in the 
WHO list of essential medicines), and along with its nucleoside analogue 5-fluoro-2’-deoxyuridine 
(FdUrd, 2), is still in clinical use to treat patients with solid tumours including colon, gastric, breast 
and pancreatic carcinoma (Table 1). In order to exert activity, both compounds after intracellular 
uptake need to be metabolized to the 5’-monophosphate form FdUMP (I), which forms a stable 
ternary complex with thymidylate synthase (TS) and the reduced co-factor 5,10-
methylenetetrahydrofolate (5,10-CH2-THF) acting as a source of the methyl group. The presence of 
fluorine being more tightly bound to carbon (C-5) than hydrogen in FdUMP, prevents -elimination 
reaction to occur with release of TS enzyme.  As a consequence, the TS remains trapped in the 
TS/FdUMP/mTHF ternary complex causing irreversible inhibition of its enzymatic function 
[31][32]. Therefore, a formation of TMP, a building block for DNA synthesis and repair, is 
diminished. However, the effectiveness of 5-FU (1) in the clinic is limited since less than a third of 
patients achieve objective responses [33]. Moreover, inherent and acquired resistance mechanisms 
that are usually associated with the nucleoside analogue 5-FU (such as decreased cellular uptake, 
decreased activation to the 5’-monophosphate form by thymidine kinase or overexpression of TS) 
have been also reported. Many prodrugs of 5-FU (1) including capecitabine (5), tegafur (52), 
doxifluridine (furtulon, 53), and carmofur (54) have been developed to address the key resistance 
mechanisms and are currently in use in the clinic. An orally administrated capecitabine (5) is 
recognized as the most important prodrug of 1 and as a single agent is used for the treatment of 
metastatic breast cancer (that is resistant to both paclitaxel and anthracycline), metastatic colorectal 
cancer and adjuvant colon cancer [34].  
One of the most effective strategies that address the key resistance mechanisms associated 
with nucleoside analogues in the clinic is the phosphoramidate (ProTide) technology. Delivery of 
the free 5’-monophosphate form of a nucleoside analogue inside a cell is particularly important as 
the first phosphorylation is considered as the rate-limiting step in the activation of most nucleoside 
analogues. The application of the 5’-phosphoramidate approach to FdUrd (2) led to the discovery 
and further clinical development of L-alanine-based 5’-ProTide NUC-3373 (55) [35]. Preclinical in 
vitro data has shown that NUC-3373 exerts its cytostatic activity independently of thymidine kinase 
in TK-deficient cell lines. In addition, NUC-3373 is resistant to the degradative action of catabolic 
enzymes such as thymidine phosphorylase (TP), an enzyme often upregulated in tumour cells or 
expressed in mycoplasma-infected tumour tissue [36], and dihydropyrimidine dehydrogenase 
(DPD), an enzyme abundantly expressed in the liver. The cytostatic potency of ProTide 55 is 
maintained in the tumour cell lines that lack hENT1 transporter (CEM/hEnt-0) whilst that of FdUrd 
(2) is reduced by 63-fold [37]. Moreover, in vitro NUC-3373 generates up to 363-fold higher 
intracellular levels of FdUMP (I) in comparison with 5-FU in human colorectal cancer cell line 
HT29. In vivo NUC-3373 achieves significantly greater tumour volume reduction than 5-FU in the 
human colorectal cancer HT29 mouse xenograft model [38]. In 2016, NUC-3373 entered into a 
Phase I clinical study in patients with advanced solid tumours (Table 1). The metabolism of 1 and 
bioactivation pathways of its derivative agents is summarised in Figure 15.  
Figure 15. Metabolism of 5-FU, and its nucleoside and nucleotide derivatives 
 
Abbreviations of structures: 5’-dFCyd: 5’-deoxy-5-fluorocytidine (56); 5'-dFUrd: 5'-deoxy-5-fluorouridine (53); 
DHFU: 5-fluorodihydrouracil (IV); FdCyd: 5-fluoro-2’-deoxycytidine (58); 5-FU: 5-fluorouracil (1); FdUrd: 5-fluoro-
2'-deoxyuridine (2); FdUMP: 5-fluoro-2'-deoxyuridine-5'-monophosphate (I); FdUDP: 5-fluoro-2'-deoxyuridine-5'-
diphosphate (II); FdUTP: 5-fluoro-2'-deoxyuridine-5'-triphosphate (III); FUMP: 5-fluorouridine-5'-monophosphate 
(V); FUDP: 5-fluorouridine-5'-diphosphate (VI); FUTP: 5-fluorouridine-5'-triphosphate (VII); Enzymes: CDA: 
cytidine deaminase; DPD: dihydropyrimidine dehydrogenase; OPRT: orotate phosphoribosyl transferase; RNR: 
ribonucleotide reductase; TK: thymidine kinase; TS: thymidylate synthase; TP: thymidine phosphorylase; Inhibition is 
represented by dashed lines. 
Metabolic pathways of 5-FU and its nucleoside/nucleotide derivatives: i(a-c): (a) cleavage of N4-pentyl-
carbamate in capecitabine (5) by carboxylesterase (in liver) to form 5’-dFCyd (56); (b) CDA-mediated deamination of 
5’-dFCyd (56) to 5’-dFUrd (53) (in liver, or tumour); (c) TP-mediated conversion of 5’-dFUrd (53) to 5-FU (1); ii: 
Successive oxidation at the hexylcarbamoyl side-chain followed by excision of the side-chain from the pyrimidine ring; 
iii: Deamination of flucytosine (57) by cytosine deaminase; iv: Hydroxylation of Tegafur (52) to form 5’-
hydroxytegafur followed by spontaneous decomposition to 5-FU (1); v: CDA-mediated deamination of FdCyd (58) to 
FdUrd (2); vi(a-d): (a) Hydrolysis of the ester moiety in the 5’-ProTide NUC-3373 (55) mediated by carboxyesterase-
type enzyme; (b) spontaneous cyclization with displacement of the aryl moiety; (c) spontaneous hydrolysis of cyclic 
mixed anhydride intermediate; (d) P-N bond cleavage mediated by phosphoramidase-type enzyme to deliver FdUMP 
(I). 
3.1.2 Gemcitabine and prodrugs 
The second prominent and clinically widely used fluorinated anticancer agent is gemcitabine 
(2’-deoxy-2’,2’-difluorocytidine, dFdC, 4) approved for the treatment of pancreatic, non-small cell 
lung, ovarian and breast cancers [39][40]. Similarly to 5-FU, the clinical effectiveness of 
gemcitabine is limited due to resistance mechanisms caused by poor cellular uptake, poor 
conversion of gemcitabine into active metabolites by deoxycytidine kinases and/or rapid 
degradation (deamination) into the inactive potentially toxic by-product dFdU catalysed by cytidine 
deaminase [41][42][43]. The important active form of dFdC, the triphosphate metabolite (dFdC-
TP), incorporates into the DNA chain during S-phase of cell cycle causing masked chain 
termination of DNA synthesis and eventually cell death. Another key active metabolite of dFdC, the 
diphosphate form (dFdC-DP), contributes significantly to the anticancer activity of dFdC by 
inhibiting ribonucleotide reductase (RNR). This results in depletion of the natural deoxynucleotide 
pool (essential substrates for DNA synthesis) and as a consequence enhances the incorporation of 
dFdC-TP instead of natural deoxynucleotides as a substrate for DNA polymerase [44].  
In order to improve the clinical efficacy of gemcitabine, in particular to increase the 
intracellular generation of the active metabolite, dFdC-TP, as well as increasing the plasma half-
life, the level of protection from catabolic action of cytidine deaminase and bioavailability, many 
modifications at the 4-(N) and 5’-sites of gemcitabine have been applied [45]. This has led to 
development of novel gemcitabine-based prodrugs such as LY2334737 (59), CO-101 (60) and the 
phosphoramidate NUC-1031 (51) (Figure 16). LY2334737, primarily designed to block the site of 
deamination of 4, links valproic acid with gemcitabine via an amide bond at the 4-(N)-position of 
the cytosine base [46]. The first-in-human Phase I clinical trial of LY2334737 (59) as a single agent 
in patients with advanced and metastatic solid tumours has been completed [47]. An additional 
Phase Ib study of LY2334737 in a combination with capecitabine in patients with advanced solid 
tumours was designed to determine the recommended dose of 59 for future Phase II studies [48]. 
However, due to hepatic toxicities observed in patients in this study, further development of 
LY2334737 was discontinued.  
Another gemcitabine-based agent that has entered clinical trials is gemcitabine elaidate CO-
101 (CP-4126, 60). This lipophilic prodrug with an unsaturated fatty acid at the 5’-site of 
gemcitabine was designed with the aim to increase plasma membrane permeability independently 
from nucleoside-transporter systems. Inside the cell, CO-101 is first converted to free gemcitabine 
after carboxyesterase-mediated cleavage of the fatty acid chain and subsequently to its 5’-
monophosphate form (dFdC-MP) by deoxycytidine kinase [49][50]. However, in the Phase I study 
high levels of dFdU were generated suggesting that CO-101 was rapidly deaminated by CDA [51]. 
Several clinical trials for 60 (in monotherapy and in combination for advanced solid tumours) have 
been conducted. However, further clinical development of CO-101 was suspended as the agent was 
not superior to gemcitabine and no difference in overall survival between the two groups was 
achieved (in either the primary analysis of the hENT1-low patient population, or in the overall 
intent-to treat population) in metastatic pancreatic cancer trials [52][53]. 
NUC-1031 (51) is the gemcitabine L-alanine-based 5’-phosphoramidate designed to 
overcome all three of the resistance mechanisms (cellular uptake, kinase mediated phosphorylation 
and deamination) that have been associated with a poor survival prognosis to gemcitabine therapy 
[54][55][56]. After cellular uptake, independent of nucleoside transporters, 51 releases the 5’-
monophosphate form via consecutive steps mediated by the action of carboxyesterase-type enzyme 
(ester hydrolysis) and phosphoramidase-type enzyme (P-N bond cleavage) [57]. The first-in-human 
Phase I study in patients with advanced solid tumours was opened in 2012. Encouraging 
pharmacokinetics and a favourable efficacy and safety profile have been reported for NUC-1031 in 
this study. The plasma half-life of NUC-1031 was more favourable than gemcitabine (7.3 hours 
versus 1.5 hours), and NUC-1031 achieved 217 x higher intracellular dFd-CTP levels than those 
reported for gemcitabine [58]. Final results of the first-in-human Phase I study of NUC-1031 in 
patients with solid tumours indicated the achievement of durable disease control in a high 
proportion of patients including patients refractory to, or who relapsed on prior gemcitabine therapy 
[59]. Currently, NUC-1031 is being assessed in several clinical studies for the treatment of patients 
with ovarian, biliary and pancreatic cancers as shown in Table 1.  
3.1.3  Other pyrimidine-based anticancer fluorinated nucleoside analogues 
 
Trifluorothymidine (TFT, 7) is a 5-CF3-bearing nucleoside analogue closely related to thymidine. 
Within the cell, TFT is phosphorylated by thymidine kinase to the corresponding 5’-monophosphate 
form as one of its active metabolites which reversibly inhibits thymidylate synthase (TS) by binding 
to the active site of the enzyme [60]. The 5’-monophosphate form of TFT is a substrate for further 
phosphorylation steps to give 5’-di- and 5’-triphosphate forms. The triphosphate form of TFT 
(TFT-TP) is also an active metabolite that can be incorporated into DNA strands with subsequent 
induction of fragmentation [61][62]. The key resistance mechanism associated with the use of TFT 
is its rapid degradation to 5-carboxy-2’-deoxyuridine (5-COOH-dU), 5-trifluorouracil (5-CF3-U), 
and 5-carboxyuracil (5-COOH-U) by the action of thymidine phosphorylase [63][64]. Although 
encouraging initial results from clinical studies on the administration of TFT to patients with breast 
and colon cancer were observed, further progression of 7 in the clinic as a single agent was halted 
due to rapid recurrence of disease in patients [65]. Trifluridine was approved in 1980 as an anti-
herpes simplex viral drug for treating cold sores and in 2015, as TAS-102 in a combination with 
tipiracil hydrochloride (a thymidine phosphorylase inhibitor in chemotherapy) for patients with 
refractory colorectal cancer. 
Tezacitabine (FMdC, 61, Figure 16), the 2’-fluoromethylene deoxycytidine nucleoside analogue of 
gemcitabine (4) exerts anticancer activity via irreversible inhibition of ribonucleotide reductase 
(RNR) by its diphosphate form (FMdC-DP). It has been postulated that the presence of fluorine in 
the 2’-vinyl moiety in FMdC-DP facilitates the 3’-hydrogen atom abstraction from the FMdC-DP, 
by resonance stabilization of the formed 3’-radical [66]. Another active metabolite of tezacitabine, 
the 5’-triphosphate form (FMdC-TP) incorporates into DNA during replication, or repair leading to 
chain termination. Tezacitabine, unlike other cytidine nucleoside analogues, is relatively resistant to 
deamination by cytidine deaminase. Moreover, tezacitabine has shown to enhance the DNA-
directed effect of capecitabine in human colon cancer cells through increasing activity of TP, one of 
the enzymes required for activation of capecitabine in tumours [67]. Phase I and II clinical trials for 
tezacitabine have been completed for haematologic malignancies and gastric cancer, respectively. 
In addition, tezacitabine was clinically assessed in Phase I and II either as a single agent or in a 
combination with 5-FU for treatment in patients with advanced oesophageal cancer or gastric 
cancer. In 2004, further development of tezacitabine was terminated as it failed to meet Phase II 
trial endpoints. 
 
Figure 16. Fluorinated anticancer nucleobase, nucleoside and nucleotide analogues in clinical 
studies 
Fluorocyclopentenylcytosine (RX-3117, 62) is an orally available, cytosine analogue of naturally 
occurring neplanocin A with a fluorinated cyclopentenyl moiety (Figure 16) [68]. RX-3117 has 
anticancer activity in a number of human tumour xenografts. Its metabolic activation begins, after 
nucleoside transporter 1 (hENT-1) mediated uptake, with a phosphorylation step to 5’-
monophosphate (RX-MP) performed by UCK2, one of two uridine-cytidine kinase (UCK) [69][70], 
and subsequent two phosphorylations to the 5’-di-and triphosphate forms. The latter form (RX-TP) 
can be incorporated to RNA, whereas the 5’-diphosphate (RX-DP) can be reduced by RNR to its 
deoxy-analogue (dRX-DP) which can be further converted to the triphosphate form (dRX-TP) and 
incorporated into DNA. Moreover, RX-3117 can act as an effective demethylating agent by 
inhibiting DNA methyltransferase (DNMT). Interestingly, unlike gemcitabine, RX-3117 is a poor 
substrate for cytidine deaminase (CDA) as shown by Peters et al. in their in vitro studies in the 
U397 cell line simultaneously treated with RX-3117 and tetrahydrouridine (THU), an inhibitor of 
CDA enzyme [69]. A first-in-human trial of RX-3117 in patients with solid tumours has been 
completed and demonstrated encouraging evidence of the single agent safety and tolerability [71]. 
Currently, patients are being recruited for two Phase I/II clinical trials focusing on adverse 
reactions, therapeutic use and proof of concept for RX-3117 use in patients with pancreatic and 
bladder cancer [71]. 
3.2 Purine-based anticancer fluorinated nucleoside analogues 
Fludarabine (FAMP, 3) represents an effective and extensively investigated purine nucleoside 
analogue in indolent B-cell malignancies, and is used as a first- and second-line agent in the 
treatment of B-cell chronic lymphocytic leukaemia (B-CLL) [72]. Fludarabine is also used in 
combination treatment, particularly in chemoimmunotherapy in combination with the DNA-
alkylating agent cyclophosphamide, and the monoclonal antibody rituximab to treat CLL patients 
[73]. Structurally, fludarabine is the 5’-monophosphate form of 2’-fluoro-arabinofuranosyladenine 
and as such, being negatively charged at physiological pH, is unable to enter cells. Thus, 
fludarabine is first dephosphorylated to its antimetabolite, F-ara-A which after cellular uptake by 
nucleoside transport systems is re-phosphorylated by deoxycytidine kinase to the 5’-monophosphate 
form and subsequently to the 5’-di and 5’-triphosphate forms by adenylate kinase and nucleoside 
diphosphate kinase, respectively. The major active metabolite of fludarabine is the 5’-triphosphate 
(F-ara-ATP), which as an alternative substrate to the natural deoxynucleotide (dATP), inhibits DNA 
polymerases. Moreover, F-ara-ATP can inhibit other enzymes involved in DNA synthesis such as 
DNA primase, DNA ligase and ribonucleotide reductase [74][75][76]. Although the presence of 
fluorine in F-ara-A increases its relative resistant to deamination by adenosine deaminase [77], F-
ara-A can be a subject to phosphorolytic cleavage with the release of 2-fluoroadenine (F-Ade), a 
metabolite known to accumulate as the toxic triphosphate F-ATP [78]. In fact, many clinical trials 
have shown that administration of fludarabine may cause (in a dose dependent manner) severe 
central nervous toxicity (dementia, coma), elevation of liver enzyme levels, and transient 
somnolence [79][80][81].  
Several resistance mechanisms associated with fludarabine have been reported and they are mainly 
related to biochemical alterations in membrane nucleoside transporters, deoxycytidine kinase and 
cytoplasmic 5-nucleotidase cN-II activities, and to changes in the expression of miR-34a (small 
non-coding RNA molecule mediating post-transcriptional gene silencing) [82]. In addition, over-
expression of miR-181, miR-221, MYC, SULF2 and down-regulation of miR-29a has been reported 
in CLL patients resistant to fludarabine [83].  
Clofarabine (Cl-F-ara-A, 6) is a second-generation chemotherapeutic agent that has been 
designed with the aim to combine structural features of cladribine and fludarabine [84]. Introduction 
of the fluorine atom into the 2’-arabino position in the scaffold of cladribine gave rise to the 
structure of clofarabine with increased stability at pH 1 [84]. In addition, clofarabine shows 
resistance to phosphorolytic cleavage and the deamination process. Clofarabine as a clinical agent is 
approved for the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemias, 
and is also being investigated in combination therapy to treat patients with chronic lymphocytic 
leukaemia, acute myelogenous leukaemia and myelodysplastic syndrome [85]. Clofarabine can 
enter cells using either facilitated or active nucleoside transport mechanisms and, when at higher 
concentration and upon longer exposure, by passive diffusion across the lipid membranes [86]. 
Once inside the cell, clofarabine, like other nucleoside analogues, is phosphorylated to its 5’-
monophosphate form by cytosolic deoxycytidine kinase (dCK) as well as mitochondrial 
deoxyguanosine kinase (dGK) [87]. Subsequently the diphosphate is converted to its active species, 
the 5’-triphosphate metabolite (Cl-F-ara-ATP) [87]. There are three major mechanisms by which 
clofarabine exerts its anticancer activity, and these include inhibition of ribonucleotide reductase, 
inhibition of DNA synthesis, and direct induction of apoptosis [88]. The clofarabine triphosphate 
form, as an adenosine analogue, can be incorporated by DNA polymerase and lead to DNA chain 
termination. The fluorine atom, with its electron-withdrawing properties, has been postulated to 
affect the reactivity of the 3’-OH group and/or the three-dimensional structure of DNA in such a 
way that incorporation of other nucleotide analogues and hence extension of DNA chain terminated 
with 2’-fluoro-containing nucleosides is inhibited [89]. In addition, clofarabine may also contribute 
to RNA-directed events such as inhibition of the polyadenylation process being one of the key steps 
in the post-transcriptional RNA processing essential for the synthesis and maintenance of mRNA 
transcripts [90]. Resistance mechanisms commonly associated with nucleoside analogues have been 
reported also for clofarabine. It has been also hypothesized that the activity of dCK for which 
clofarabine is a good substrate, may modulate ABCG2-mediated resistance as clofarabine 
cytotoxicity can be strongly reduced by enhanced ABCG2-mediated efflux [91]. Recently, 
clofarabine has also been reported as a dual-action inhibitor of HIV-1 replication by both limiting 
dNTP substrates pool for viral DNA synthesis and by inhibiting the DNA polymerase activity of 
HIV-1 reverse transcriptase [92]. 
4.  Antiviral fluorinated nucleosides 
In the last two decades, major advances for the treatment of several viral infections have been 
achieved. On the other hand, an outburst of novel viral diseases has featured in recent years, for 
which effective therapies do not exist. Ebola, Zika and also new strains of hepatitis and herpes 
viruses have spread with potential for a pandemic outbreak. There are three main classes of viral 
infections. The first class includes life threatening chronic viruses like the human 
immunodeficiency virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) viruses. The second 
class comprises acute viral infections such as influenza that are generally non-lethal and self-
resolving. The third class includes viral infections (common cold caused by rhinoviruses) that are 
non-lethal but have a significant economic impact [93]. 
Nucleoside analogues represent a very successful class of antiviral agents. Compared to the 
anticancer nucleosides, they are structurally more diverse as they include nucleosides, acyclic 
nucleosides and nucleotides. Additionally, they show a better tolerance profile compared to the 
anticancer nucleosides due to a low level of activity on mammalian enzymes. In order to exert their 
antiviral activity, they are converted to their 5’-triphosphate form. The target of nucleoside reverse 
transcriptase inhibitors (NRTis) is usually the viral polymerase. The class of NRTi include the 
compounds mimicking the endogenous natural nucleosides and those that need to be 
phosphorylated to their 5’-triphosphate form in order to exert biological activity. Viral polymerase 
catalytic residues interact with the template, the primer and with the incoming nucleoside 5’-
triphosphates [93].  
Nowadays, nucleoside analogues are used in the clinic or in clinical development for the 
treatment of several diseases such as HBV, HCV, HIV, human respiratory syncytial virus (HRSV), 
human cytomegalovirus (HCMV), and Varicella zoster virus (VZV). Despite their widespread use, 
many limitations are associated with antiviral chemotherapy and resistant viral strains are common. 
For this reason, research is focusing on the development of new nucleoside analogues which can 
overcome the resistance mechanisms [93]. Many of these compounds are characterized by the 
presence of fluorine that has improved biological profiles and provided improved metabolic 
stability. The properties and expectations that an antiviral drug needs to meet and the acceptable 
level of toxicity vary according to the type and gravity of the disease. Examples of fluorinated 
antiviral nucleoside analogues and derivatives (63-75) in the clinic and clinical trials are reported in 
Figure 17.  
 Figure 17. Fluorinated antiviral nucleoside analogues and derivatives in clinical trials. 
 
4.1 Pyrimidine-based antiviral fluorinated nucleosides and prodrugs 
 
The first antiviral nucleoside, Iduviran, was synthesised by Prusoff et al. in 1959 [94] and soon 
after, a 2’-fluorinated derivative was synthesised in order to stabilise the glycosidic bond that was 
unstable in acidic conditions [95]. Several uridine and cytidine derivatives were subsequently 
synthesised; in particular 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC, 
63), and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluridine (FMAU, 64) showed a 
very good activity against HSV, HBV and other viruses such as CMV and Epstein–Barr virus 
(EBV) [95][96]. L-FMAU (65), also known as clevudine, is a very potent antiviral agent for the 
treatment of HBV. It was approved in South Korea in 2006 [97][98] but recently a Phase III clinical 
trial was halted due to cases of myopathy in some patients. It was then revoked also from the South 
Korean market. [99] 
Many other 2’-fluorinated nucleosides have been synthesised more recently and studies on 
the SAR showed that fluorine in the 2’-arabino-position (up) or in the 3’-ribo-position (down) leads 
to an increased anti-HIV activity [95]. FIAU (66) has been selected as a Phase I clinical trial 
candidate, but it showed mitochondrial toxicity resulting in lactic acidosis and hepatic failure [100]. 
Martin et al. have synthesised a variety of 2’-deoxy-2’-fluoro-pyrimidine based nucleosides and, 
among them, many fluorinated analogues of 2′,3′-dideoxycytidine (ddC), which have showed 
significant anti-HIV activity [101]. 
Mericitabine (RG-7128, 67) is a 3’,5’-diisobutyrate prodrug of 2′-deoxy-2′-fluorocytidine 
(FdC) with potent anti-HCV activity [50]. It has successfully completed Phase I and II clinical trial 
either alone or in combination with pegylated-interferon and ribavirin or in combination with a first 
generation of protease inhibitor [102][103]. A clinical trial with mericitabine and other agents in an 
interferon-free regime was also very successful and clinical trials are likely to continue [52]. 3'-
fluoro-3'-deoxythymidine (FLT, 68), also known as Alovudine, was one of the first antiviral 
compounds synthesised in 1971 [104] but its anti-HIV activity was not discovered until 1988 [105], 
showing a major potency compared to azidothymidine (AZT), an established agent for the treatment 
of HIV [106]. Alovudine inhibits in vitro replication of highly resistant nucleoside reverse 
transcriptase inhibitor (NRTI) HIV strains. However, due to dose-dependent safety concerns in 
initial development, further clinical investigations of Alovudine were halted [107]. 
 Phosphoramidate prodrugs of FLT have been synthesised and in vitro studies showed potent 
inhibition of HIV-1 and HIV-2 replication, although they were less potent in comparison to the 
parent nucleoside [108]. Emtricitabine (FTC, 8) is a 5-fluorodeoxycytidine derivative, with an 
uncommon sugar, an oxathiolane ring. It is an inhibitor of reverse transcriptase (NRTI) and is used 
for the treatment of HIV infection [98]. Emtricitabine is included in the list of the essential 
medication compiled by the World Health Organization [109]. It is chemically similar to the 
antiviral agent lamivudine and its triphosphate form incorporates faster into growing viral DNA in 
comparison with lamivudine. Although very active, there are some concerns about the fact that it 
could be inactive against lamivudine-resistant HBV strains and that it could be associated with 
similar HBV-resistant mutant development. Nevertheless, the presence of the fluorine boosts its 
bioavailability and half-life compared to lamivudine [110]. Racivir (69) the enantiomer of 8, 
showed also potent anti-HIV activity and studies in vitro have revealed that this agent is also active 
against HBV [111]. 
Elvucitabine (70) is another 5-fluoro NRT inhibitor active as anti-HIV and HBV agent that 
has recently completed Phase II clinical trial for the treatment of HIV [112]. Favipiravir (T-705, 71) 
is a fluorinated pyrazine carboxamide derivative effective in the treatment of influenza viruses. 
Introduction of fluorine at the 6-position of the pyrazine ring improved the biological activity and 
pharmacokinetic properties of T-705 when compared to other derivatives [113]. It is currently used 
in Japan for the treatment of influenza virus and clinical trials are ongoing in the United States. T-
705 is converted into the ribofuranosyl triphosphate form by endocellular enzymes and it inhibits 
the influenza viral polymerase [114]. After the 2014 outbreak of Ebola virus disease (EVD), a lethal 
condition with no specific treatment yet approved, a multicenter non-randomized trial with 
favipiravir and standardized care was conducted. Although the trial did not conclude on the efficacy 
of the drug, it suggests that further studies should be conducted with a favipiravir monotherapy in 
patients with medium to high viremia [115][116]. 
Sofosbuvir (Sovaldi®, GS7977, 72), the nucleotide prodrug of -D-2’-deoxy-2’--fluoro-
2’--C-methyluridine, is an anti-HCV inhibitor of the NS5B RNA polymerase with a pan-genotypic 
antiviral activity. Non-structural protein 5B (NS5B) is an RNA-dependent RNA polymerase 
responsible for the synthesis of both positive and negative-strand genomic RNA.  This enzyme is 
essential for sofosbuvir as 72 acts by mimicking the natural substrate of NS5B polymerase. Once 
incorporated into the growing RNA, it induces chain termination. It was first synthesized as a 
diastereoisomeric mixture (GS-9851), comprising sofosbuvir (GS-7977, Sp isomer) and GS-491241 
(RP isomer), with potent inhibitory activity towards the NS5B enzyme [117][118]. Studies in vitro 
showed that GS-9851 is converted into an inactive, achiral intermediate by the enzymes cathepsin A 
(CatA) and carboxylesterase 1 (CES1). It is then hydrolysed by an histidine triad nucleotide-binding 
protein 1 (Hint1) into an inactive 5’-monophosphate form which is further phosphorylated to the 
corresponding 5’-diphosphate form by uridine-monophosphate-cytidine-monophosphate kinase 
(UMP-CMP) and finally into the active 5’-triphosphate form by nucleoside diphosphate kinase, 
respectively [82][119]. Sofosbuvir shares the same metabolic pathways as the diastereoisomeric 
mixture and, because of this specific metabolism, it has a low potential for cytochrome P450-
mediated drug-drug interactions. It has showed an impressive sustained virological response rates 
(SVR) (over 90% of patients) compared to other anti HCV agents and high genetic barrier to 
resistance. This makes sofosbuvir essential in the care of both treatment-naïve and treatment-
experienced patients. Sofosbuvir was FDA-approved in 2013 in the USA for the treatment of 
chronic HCV infection in patients with genotypes 1, 2, 3 or 4, including those with hepatocellular 
carcinoma meeting the Milan criteria (patients awaiting for liver transplantation) and those with 
HCV/HIV-1 co-infection. In combination therapy with ribavirin, the prodrug 72 was revealed to be 
effective also in subjects co-infected with HIV. In addition, sofosbuvir prevented a recurrence of 
HCV infection in most of the patients awaiting liver transplant. Several trials with 72 and other oral 
direct-acting antivirals (DAAs) are ongoing and will provide oral interferon-free treatment regimens 
for genotype-1 infections [120]. Recently, after the pandemic spread of Zika virus, sofosbuvir has 
been also evaluated for the treatment of this disease. In vitro studies showed promising results and 
further studies need to be undertaken [121]. 
 
4.2 Purine-based fluorinated nucleosides and prodrugs 
PSI-353661 (73) and PSI-352938 (74) are both purine-based prodrugs of β-D-2'-deoxy-2'-α-fluoro-
2'-β-C-methylguanosine-5'-monophosphate. Both compounds have shown a promising in vitro anti-
HCV activity. They are characterised by a unique resistance profile that makes them desirable 
candidates for a combination therapy with other HCV inhibitors including other nucleosides and 
analogous nucleotides. They are currently under clinical evaluation [122]. GS9131 (75) is another 
2’-F- purine-based phosphonamidate which has been shown to inhibit HIV-1 reverse transcriptase 
(RT) and proved to have a unique resistance profile toward N(t)RTI resistance mutations. GS9131 
is currently under clinical evaluation [123]. 
 
Table 1 brings together the various anticancer and antiviral fluorinated nucleosides that have 
entered clinical development, along with information on the drug developer, disease indication and 
molecular target. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Fluorinated NAs and their prodrugs in clinical use and clinical development for cancer 
Data in Table 1 were taken from the references 22, 33 and 45 and references therein.  Additional references are included 
in the main text body. Information about status of clinical trials available from www.clinicaltrials.gov 
 
 
 
 
 
 
 
 
Drug Name Originator/Developer Phase Disease Target               
Fluorouracil (5-FU, 1) Roche Approved (1962) Colorectal, breast, pancreatic, stomach cancer TS
Floxuridine (FdUrd, 2) Roche Approved (1970) Liver metastasis TS
Capecitabine (5) Roche Approved (1998) Metastatic breast, colorectal cancer TS
Tegafur (52) + Uracil Taiho Pharmaceutical
Used in Japan, Taiwan
II
II/III
Advanced GI cancers
Colon, combination therapy for hepatocellular carcinoma
Gastric cancer
TS, DNA synthesis
 inhibition
Tegafur (52) + Gimeracil + Oteracil
Taiho Pharmaceutical III
Advanced gastric cancer in combination with cisplatin
TS
Doxifluridine (53) Aida Pharmaceuticals III Combination therapy for GI cancer TS
FdCyd(58) + THU National Cancer Institute I and II Neoplasms DNA methyltransferase
Flucytosine (57) Tocagen I/II
I
Combination therapy for solid tumours
Brain tumours
TS
NUC-3373 (55) NuCana I Colorectal and breast cancer TS
Gemcitabine (4)
Eli Lilly Approved (1996)
Non-small cell lung, breast, pancreatic,ovarian, soft tissue 
sarcoma
DNA polymerase
RNR, dCMP deaminase
LY2334737 (59) Eli Lilly Discontinued Malignant and metastatic solid tumours
DNA synthesis 
inhibition
CO-101 (60) Clavis Pharma Discontinued 
Advanced solid tumours
Metastatic pancreatic dual adenocarcinoma
DNA synthesis 
inhibition
NUC-1031 (51) NuCana
III
II
I
Pancreatic cancer
Ovarian cancer 
Combination therapy for ovarian and biliary tract cancers
DNA synthesis 
inhibition
RX-3117 (62) Rexahn Pharmaceuticals/TEVA
Pharmaceuticals
I/II
I
Solid tumours
Combination therapy for ovarian cancer
DNA methyltransferase
Tezacitabine (61) Aventis/Chiron Corporation Discontinued Hematological malignancies RNR
Trifluorothymidine (7) + Tipiracil 
HCl (TAS-102)
Taiho Pharmaceutical Approved (2015) Metastatic colorectal cancer TS
Fludarabine (3)
Southern Research Institute/
Bayer HealthCare 
Pharmaceuticals
Approved (1991) Hairy cell leukemia, B-cell CLL
DNA polymerase, 
RNR, DNA primase
Clofarabine (6)
Bioenvasion Approved (2004) Pediatric refractory ALL DNA polymerase, RNR
  
Table 1 (cont.) Fluorinated NAs and their prodrugs in clinical use or clinical development for viral 
infections 
 
Data in Table 1 (cont.) were taken from the references: 1, 95, 98 and 112 and references therein. Additional references 
are included in the main text body. Information about status of clinical trials available from www.clinicaltrials.gov 
Conclusion 
In this review we summarise electrophilic and nucleophilic fluorination methods, including 18F-
radiolabeling used in the synthesis of fluorine-containing nucleoside analogues. The modulatory 
and beneficial effect on pharmacological properties of molecules that fluorine incorporation at an 
appropriate position imparts is well known and reported. Along with cellular biology of FDA-
approved fluorinated nucleoside analogues and derivatives, we emphasise some profound effects 
fluorine adds to nucleos(t)ide analogues such as clofarabine and tezacitabine or FdUrd-MP. These 
effects include increased stability towards deamination and phosphorolytic cleavage or target/ligand 
binding properties, respectively. We also outline current developments and strategies aiming to 
Drug Name Originator/Developer Phase Disease Viral Target
Trifluorothymidine (7) 
Viroptic
GlaxoSmithKline Approved (1998) Herpes Simplex Virus (HSV) DNA polymerase
Emtricitabine  (8)
Emtriva
Emory University/Gilead Approved (2003) Human Immunodeficiency Virus (HIV) Nucleoside reverse transcriptase
Sofosbuvir  (72)
Sovaldi
Gilead Approved (2013) Hepatitis C (HCV)
NS5B RNA-dependent RNA
polymerase
Mericitabine (67) Pharmasset/Hoffmann-LaRoche II HCV
NS5B RNA-dependent RNA
polymerase
Favipiravir (71) Toyama Chemical/MediVector
Approved in Japan (2014)
III
JIKI trial
As stockpiling against Influenza Pandemics
Influenza
Ebola
RNA-dependent RNA polymerase
Fiacitabine (63, FIAC)
Memorial Sloan-Kettering Cancer 
Center/Oclassen Pharmaceuticals 
II Cytomegalovirus and HIV infections 
DNA polymerase
RNR
Elvucitabine (70)
Yale University/Achillion 
Pharmaceuticals
II Chronic HIV infections Nucleoside reverse transcriptase
Racivir (69) Emory University/Pharmasset II HIV Nucleoside reverse transcriptase
Fialuridine (66, FIAU) Oclassen Pharmaceuticals/Eli Lilly Discontinued HSV, HIV, and Hepatitis B (HBV) DNA polymerase
Clevudine (65, L-FMAU) Bukwand/Pharmasset Discontinued HBV DNA polymerase
Alovudine (68, FLT)
Medivir/Beijing Mefuvir Medicinal 
Technology
Discontinued HIV DNA polymerase
PSI 353661 (73) Pharmasset Preclinical development HCV
NS5B RNA-dependent RNA
polymerase
PSI 352938 (74) Pharmasset I HCV
NS5B RNA-dependent RNA
polymerase
GS9131 (75) Gilead I HCV Nucleoside reverse transcriptase
improve a clinical outcome of fluorine-containing nucleoside analogues. Given the unique features 
and desirable characteristics that fluorine can imparts to drugs, its bioisosteric replacement of 
hydrogen will continue to be used in medicinal chemistry as a method for improving and 
influencing pharmacodynamic and pharmacokinetic properties. 
Executive summary: 
 
 
 In this review, we briefly discuss the most important fluorinated nucleosides from a 
biological perspective, highlighting the contribution of fluorine to therapeutic activity. 
 As a uniquely small and electronegative atom, fluorine plays an important role within 
many drug molecules, imparting a variety of physicochemical properties influencing 
molecular stability, solubility and target binding properties.  
 Combining the benefits of fluorine incorporation with the established nucleoside class of 
therapeutics has resulted in a number of clinically proven drug molecules or clinical drug 
candidates, mainly in the fields of antiviral and anticancer therapy.  
 Recent developments in fluorine incorporation chemistry using nucleophilic fluoride have 
been instrumental in the evolving field of 18F PET radiochemistry. 
 There are significant drawbacks associated with nucleoside therapeutics, such as the 
necessity for transport-mediated uptake plus the requirement for enzyme-mediated 5’-
triphosphorylation. 
 To circumvent the drawbacks of nucleosides as therapeutic agents, we outline the 
application of phosphoramidate-based pro-nucleotide (ProTide) approaches to improve 
therapeutic outcome, illustrated by the registered drug sofosbuvir (hepatitis C) and the 
clinical candidate NUC-1031 (solid tumours). 
 
Future Perspective: 
- Fluorine incorporation strategies will continue to be strategically employed in drug discovery and 
development to improve pharmacokinetic and pharmacodynamic properties of candidate molecules. 
- The concept of activated nucleotide prodrugs (ProTides), which has recently achieved clinical 
success (e.g. sofosbuvir for Hepatitis C treatment), will continue to improve the efficacy profile of 
established nucleoside drugs whose efficacy is limited by poor cellular uptake and the requirement 
for phosphorylation. 
- Technologies for incorporation of the positron-emitter 18F (half-life 109 minutes) will continue to 
develop, driving the development of 18F-labelled nucleosides for in vivo biomarker or drug 
distribution studies using PET imaging. 
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